We invest £750,000 into each SRC, providing funding for three to four years of research.
Through our SRCs we aim to:
- Create clusters of world class researchers.
- Bring researchers from different fields or disciplines together, to tackle the complex problems in cystic fibrosis.
- Widen awareness of cystic fibrosis research outside the traditional biomedical disciplines and so attract high quality investigators from new research disciplines.
- Recruit the brightest and best young researchers to cystic fibrosis research. Each SRC provides funding for five or six young scientists, who will work alongside the experts. Investing in these scientists at this stage in their careers leads to long-lasting interest in the field.
In our five-year research strategy, 'Investing in Research to Change Lives', we set out a commitment to fund two SRCs in 2013-14. However, because we received three extraordinarily high quality applications, extra funding was found to enable us to support a third. The first two SRCs were announced in February 2014, and the third followed in April. Since, we have funded a total of twelve ground-breaking research centres.
Find out how to apply
Pseudomonal infection in CF: better detection, better understanding, better treatment.
(Imperial College London, University of Amsterdam and Catholic University of the Sacred Heart, Rome)
INOVCF: Innovative non-CFTR approaches for cystic fibrosis therapy.
(Newcastle University, University of Lisbon, University of Regensburg, University of North Carolina and University of Heidelberg)
Tackling Mycobacterium abscessus infection in cystic fibrosis.
(University of Cambridge, Sanger Institute and Colorado State University)
Harnessing data to improve lives.
(Imperial College London, University of Liverpool, University of Nottingham, London School of Hygiene and Tropical Medicine, The Hospital for Sick Children, Toronto and Norwich Medical School)
Investigating the F508del-CFTR protein.
(University of Bristol, Université de Poitiers, Utrecht University, The University of Manchester and University College London)
Personalised engineered cell therapies for cystic fibrosis.
(University College London, St George’s University of London, University College London, University College Cork)
Physical activity, exercise, sport and recreation promotion for adolescents with cystic fibrosis.
(University of Exeter, University College London, Institute of Child Health, La Trobe University, The Hospital for Sick Children (Toronto, Canada), Swansea University)
Cystic fibrosis-related diabetes research.
(Newcastle University, Ulster University, Lund University (Sweden), Szeged University (Hungary), Iowa University (USA)
Targeting joint disease in cystic fibrosis: identifying therapeutic targets in CF arthropathy.
(Leeds Institute of Rheumatic and Musculoskeletal Medicine, University Hospitals South Manchester, St James Hospital Leeds, Lausanne University & Centre of Infection and Immunity Switzerland, Chapel Allerton Hospital Leeds, Manchester Royal Infirmary)
Novel therapies for Mycobacterium abscessus.
(University of Cambridge, Wellcome Trust Sanger Institute and Colorado State University)
Mycobacterium abscessus is a type of bacteria that can cause devastating lung infections in people with cystic fibrosis. It is very difficult to treat and is growing in frequency around the world. This SRC aims to use a mixture of existing expertise and cutting-edge technologies that have been developed for other purposes to develop new antibiotics and other ways of preventing and fighting this infection, and to strengthen existing treatments.
Restoring fluidity in the gut
(University of Liverpool, University of Bristol, Erasmus University Medical Centre, Hannover Medical School, Sheffield Children's Hospital, University of Sheffield, Hadassah University Hospital)
Find out how researchers around the world will investigate ways to prevent blockages in the gut in people with cystic fibrosis (CF) by increasing the levels of fluid in the gut to help move digested food along more easily.
The effect of gut dysbiosis on lung inflammation in cystic fibrosis
(University of Leeds, Cambridge University, Lausanne University Hospital, Wellcome Trust Sanger Institute, Leeds Beckett University)
This research aims to investigate exactly how levels of short chain fatty acids and antibiotics affect the bacteria in the gut of people with CF, and if this has any effect on inflammation in the lungs, as well as looking at options for amending the diet of people with CF to help return the range of gut bacteria present to a healthy balance.
Read Dr Janet Allen, Director of Strategic Innovation at the Trust's blog on Strategic Research Centres